Steven Pergam

Adjunct Associate Professor, Epidemiology
Associate Professor, Medicine - Allergy and Infectious Dis.



MD University of Nebraska, 1998
MPH Epidemiology, University of Washington, 2008



Fred Hutchinson Cancer Research Center
Box 358080
1100 Fairview Ave. N, E4-100
Seattle, WA 98109
View Website »


Dr. Pergam is an Infectious Diseases physician and researcher who received his MD from the University of Nebraska School of Medicine, his Infectious Diseases fellowship training at the University of Washington (UW), and his MPH from the UW School of Public Health. Dr. Pergam serves as the Medical Director of Infection Prevention at the Seattle Cancer Care Alliance (SCCA). Dr. Pergam focuses his research on the prevention and treatment of infections among immunocompromised patients, and has expertise in infection prevention and hospital epidemiology among cancer and transplant patients. He serves on numerous national committees, including the CDC’s Advisory Committee on Immunization Practices, and the National Comprehensive Cancer Network Committee on the Prevention and Treatment of Infections in Cancer. He also is an Associate Editor for BMC Infectious Diseases and Current Opinions in Infectious Diseases.

Research Interests

Dr. Pergam’s research interests involve hospital epidemiology, antimicrobial resistance, and infection prevention in immunosuppressed hosts. His research group focuses on infection prevention, resistant pathogens, antimicrobial stewardship, and on the development of novel prevention strategies for community and healthcare-associated infections in cancer and hematopoietic cell transplant patients. He has active research projects that evaluate vaccinations, water-borne pathogens, resistant bacteria, respiratory virus transmission, and fungal infections among immunocompromised hosts. He is interested in the interplay between the immune response, the microbiome, bacterial and viral infections in the respiratory and gastrointestinal systems, and their association with inflammatory complications (e.g. Graft-versus-host disease, mucositis).

Recent Publications (PubMed)

Cannabis and the Cancer Patient.
(2021 Nov 28)
J Natl Cancer Inst Monogr 2021(58): 68-77
Braun IM, Abrams DI, Blansky SE, Pergam SA

Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study.
(2021 Oct)
J Immunother Cancer 9(10):
Walti CS, Loes AN, Shuey K, Krantz EM, Boonyaratanakornkit J, Keane-Candib J, Loeffelholz T, Wolf CR, Taylor JJ, Gardner RA, Green DJ, Cowan AJ, Maloney DG, Turtle CJ, Pergam SA, Chu HY, Bloom JD, Hill JA

Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
(2021 Oct)
Transpl Infect Dis 23(5): e13719
Lindsay J, Othman J, Yong MK, Ritchie D, Chee L, Tay K, Tio SY, Kerridge I, Fay K, Stevenson W, Arthur C, Chen SC, Kong DCM, Greenwood M, Pergam SA, Liu C, Slavin MA

Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
(2021 Aug 24)
Blood Adv 5(16): 3113-3119
Hill JA, Zamora D, Xie H, Thur LA, Delaney C, Dahlberg A, Pergam SA, Leisenring WM, Boeckh M, Milano F

Association of Physician Orders for Life-Sustaining Treatment With Inpatient Antimicrobial Use at End of Life in Patients With Cancer.
(2021 Aug)
Open Forum Infect Dis 8(8): ofab361
Kates OS, Krantz EM, Lee J, Klaassen J, Morris J, Mezheritsky I, Sweet A, Tverdek F, Loggers ET, Pergam SA, Liu C

Show complete publication list